Axcella announced that its Phase 2a trial testing AXA-1125 in Long Covid has reached full enrollment. This placebo-controlled trial that enrolled 40 patients with data expected in late 3Q22. It also announced that the Phase 2 trial for AXA1125 in NASH (non-alcoholic steateohepatitis) is continuing with data announcement expected in early 3Q222, and that the Phase 2 trial in Overt Hepatic Encephalopathy (OHE) has been terminated.Phase 2a Trial In Long COVID Data Expected In Early 3Q22. This placebo-controlled trial enrolled 40 patients with Long COVID symptoms. Long COVID is estimated to affect about 20% to 30% of the patients who were infected, recovered or were asymptomatic, then develop post-infectious symptoms of fatigue, muscle aches, and clouded thinking (“brain fog”). AXA1125 has shown improvement in metabolic function that improve energetics and reduce symptoms. Read More >>